Institutional shares held 184 Million
1.24M calls
957K puts
Total value of holdings $11B
$74.2M calls
$57.1M puts
Market Cap $11.1B
185,824,000 Shares Out.
Institutional ownership 99.11%
# of Institutions 665


Latest Institutional Activity in BMRN

Top Purchases

Q2 2025
Assenagon Asset Management S.A. Shares Held: 1.04M ($62M)
Q2 2025
Wealth Enhancement Advisory Services, LLC Shares Held: 74.4K ($4.44M)
Q2 2025
Wesbanco Bank Inc Shares Held: 35K ($2.09M)
Q2 2025
Perpetual LTD Shares Held: 14K ($834K)
Q2 2025
Wedmont Private Capital Shares Held: 4.39K ($262K)

Top Sells

Q2 2025
North Crest Asset Manangement, LLC Shares Held: 3.51K ($209K)
Q2 2025
Davis Investment Partners, LLC Shares Held: 7.79K ($465K)
Q2 2025
Parallel Advisors, LLC Shares Held: 474 ($28.3K)
Q2 2025
Umb Bank, N.A. Shares Held: 1.94K ($115K)
Q2 2025
Sumitomo Mitsui Ds Asset Management Company, LTD Shares Held: 20.4K ($1.22M)

About BMRN

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.


Insider Transactions at BMRN

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
307K Shares
From 16 Insiders
Grant, award, or other acquisition 307K shares
Sell / Disposition
110K Shares
From 10 Insiders
Payment of exercise price or tax liability 92.5K shares
Open market or private sale 17.7K shares

Track Institutional and Insider Activities on BMRN

Follow BIOMARIN PHARMACEUTICAL INC and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells BMRN shares.

Notify only if

Insider Trading

Get notified when an Biomarin Pharmaceutical Inc insider buys or sells BMRN shares.

Notify only if

News

Receive news related to BIOMARIN PHARMACEUTICAL INC

Track Activities on BMRN